ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Discovery and Optimization of AMT-676, a CDH17-Targeting ADC for the Treatment of Advanced Gastrointestinal Cancers.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06400485 (First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
Abstract
Advanced-stage gastrointestinal (GI) cancers present an unmet need for innovative therapies, and antibody-drug conjugates (ADCs) offer promising solutions. This study investigates the antitumor efficacy and toxicity of AMT-676, a novel ADC targeting Cadherin 17 (CDH17), in GI cancers. Utilizing MabArray screening and immunohistochemistry, CDH17 was identified as a promising ADC target in GI tumors with minimal expression in healthy organs. The ADC was optimized through comprehensive in vitro and in vivo evaluations of binding affinity, cytotoxicity, pharmacokinetics, and toxicity, with antitumor potential evaluated using cell line-derived (CDX) and patient-derived tumor xenograft (PDX) models. Leveraging the T moiety-exatecan platform, we synthesized AMT-676, comprising a high-affinity CDH17-specific antibody, a hydrophilic self-immolative T1000 linker, and exatecan with a Drug-to-Antibody Ratio (DAR) of 4. AMT-676 demonstrated sustained antitumor responses across CDX and PDX GI models with diverse CDH17 expression, notably inhibiting metastatic growth in a colorectal cancer model. Cynomolgus monkey studies revealed favorable pharmacokinetics and manageable toxicity associated with AMT-676. In conclusion, we developed a novel CDH17-targeting ADC characterized by a high therapeutic index and tolerable toxicity profile, highlighting its promise for GI cancer treatment. A first-in-human, phase I clinical trial of AMT-676 in patients with advanced solid tumors is currently underway (NCT06400485).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.